redorbit.com
May 22, 2008
Posted on: Thursday, 22 May 2008, 06:00 CDT Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) today announced the selection of H. Lundbeck A/S for European commercialization of Flurizan(R), Myriad's lead therapeutic candidate for the treatment of Alzheimer's disease. Myriad and Lundbeck have...
[read full story]